Education, awareness, and research focused on improving outcomes for patients and healthcare systems affected by CHS.
About CerebroSafe
CerebroSafe is a research-focused organization dedicated to advancing scientific understanding of cannabinoid-related toxicity, neurological stress, and brain health. Our work emphasizes responsible communication, collaboration with healthcare and research partners, and long-term, data-driven development pathways.
OUR MISSION
To advance scientific research and education that improves recognition, understanding, and future treatment approaches for cannabinoid-related emergencies, including Cannabis Hyperemesis Syndrome (CHS).
What We’re Focused On?
Biological pathways associated with cannabinoid-related neurotoxicity and neurological stress
The growing burden of CHS on patients and emergency healthcare systems
Investigational strategies evaluated through preclinical and translational research
Development Status
All programs are investigational and not approved for clinical or commercial use.
A Growing Challenge for Patients and Healthcare Systems
Delayed recognition of Cannabis Hyperemesis Syndrome (CHS) can contribute to unnecessary testing, repeated emergency department visits, and prolonged patient suffering. Improving awareness and understanding of CHS is an important step toward better patient experiences and more efficient emergency care.
Cerebro-1™ Research Program
Cerebro-1 is an investigational lipid-based candidate being studied for potential relevance to cannabinoid intoxication and CHS—two conditions contributing to rising emergency department visits across the U.S. and Canada.
Our research efforts focus on understanding lipid sequestration mechanisms, evaluating formulation characteristics, planning preclinical studies, and collaborating with experts in toxicology and emergency care.